A Case Report of Malignant Perivascular Epithelioid Cell Tumors of the Uterus and Literature Review

References

• Gadducci A, Zannoni GF. Perivascular epithelioid cell tumors (PEComa) of the female genital tract: a challenging question for gynaecologic oncologist and pathologist. Gynecol Oncol Rep. 2020;33:100603. doi:10.1016/j.gore.2020.100603
   PubMed Web of Science ®Google Scholar
• Czarnecka AM, Skoczylas J, Bartnik E, et al. Management strategies for adults with locally advanced, unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa): challenges and solutions. Cancer Manage Res. 2023;15:615–623. doi:10.2147/cmar.S351284
   PubMed Web of Science ®Google Scholar
• Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015;19(5):359–368. doi:10.1016/j.anndiagpath.2015.06.003
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Unni K, Mertens F. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC press; 2002.
   Google Scholar
• Azad NS, Aziz AB, Pervez S, et al. Uterine perivascular epithelioid cell tumour presenting as a cervical mass. J Pak Med Assoc. 2006;56(2):83–84.
   PubMedGoogle Scholar
• Tang X, Feng M, Shen Y, et al. Perivascular epithelioid cell tumor of the uterine cervix identified on the liquid-based cytology: a case report. Diagn. Pathol. 2023;18(1):7. doi:10.1186/s13000-023-01290-3
   PubMed Web of Science ®Google Scholar
• Zhang C, Pan F, Qiao J, et al. Perivascular epithelioid cell tumor of the cervix with malignant potential. Int J Gynaecol Obstet off Organ Int Fed Gynaecol Obstet. 2013;123(1):72–73. doi:10.1016/j.ijgo.2013.06.013
   PubMed Web of Science ®Google Scholar
• Sharmila V, Balakrishnan P, Arun Babu T. PEComa of Uterine Cervix. Ind J Surg Oncol. 2021;12(4):686–687. doi:10.1007/s13193-021-01416-3
   PubMed Web of Science ®Google Scholar
• Bennett JA, Braga AC, Pinto A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors. Am J Surg Pathol. 2018;42(10):1370–1383. doi:10.1097/pas.0000000000001119
   PubMed Web of Science ®Google Scholar
• Nitahara K, Sasaki M, Ichikawa S, et al. Rupture of perivascular epithelioid cell neoplasm at 34 weeks’ gestation: a nonendometriosis case of spontaneous hemoperitoneum in pregnancy. J Obst Gynaecol Res. 2019;45(3):709–713. doi:10.1111/jog.13870
   PubMed Web of Science ®Google Scholar
• Babayev E, Fay KE, Horowitz JM, et al. Perivascular epithelioid cell tumors (PEComa) in pregnancy with uterine rupture and ongoing abdominal gestation: a case report. Case Rep Wom Health. 2020;25:e00172. doi:10.1016/j.crwh.2020.e00172
   PubMedGoogle Scholar
• Nguyen JMV, Ghandehari H, Parra-Herran C, et al. Uterine rupture: an unusual presentation of a uterine perivascular epithelioid cell tumor (PEComa). Intern J Gynecolog Can. 2020;30(12):2008–2011. doi:10.1136/ijgc-2020-001837
   PubMed Web of Science ®Google Scholar
• D’Augè TG, Giannini A, Bogani G, et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin Exp Obstet Gynecol. 2023;50(8). doi:10.31083/j.ceog5008160
   Web of Science ®Google Scholar
• Gammill LS, Bronner-Fraser M. Neural crest specification: migrating into genomics. Nat Rev Neurosci. 2003;4(10):795–805. doi:10.1038/nrn1219
   PubMed Web of Science ®Google Scholar
• Stone CH, Lee MW, Amin MB, et al. Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum. Arch Pathol Lab Med. 2001;125(6):751–758. doi:10.5858/2001-125-0751-ra
   PubMed Web of Science ®Google Scholar
• Shen J, Shrestha S, Yen YH, et al. Pericyte antigens in angiomyolipoma and PEComa family tumors. Med Oncol. 2015;32(8):210. doi:10.1007/s12032-015-0659-y
   PubMed Web of Science ®Google Scholar
• Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Prim. 2016;2:16035. doi:10.1038/nrdp.2016.35
   PubMed Web of Science ®Google Scholar
• Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Molecular Cell. 2003;11(6):1457–1466. doi:10.1016/s1097-2765(03)00220-x
   PubMed Web of Science ®Google Scholar
• Dibble CC, Elis W, Menon S, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Molecular Cell. 2012;47(4):535–546. doi:10.1016/j.molcel.2012.06.009
   PubMed Web of Science ®Google Scholar
• Benvenuto G, Li S, Brown SJ, et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene. 2000;19(54):6306–6316. doi:10.1038/sj.onc.1204009
   PubMed Web of Science ®Google Scholar
• Huang J, Dibble CC, Matsuzaki M, et al. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28(12):4104–4115. doi:10.1128/mcb.00289-08
   PubMed Web of Science ®Google Scholar
• Schoolmeester JK, Dao LN, Sukov WR, et al. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. 2015;39(3):394–404. doi:10.1097/pas.0000000000000349
   PubMed Web of Science ®Google Scholar
• Agaram NP, Sung YS, Zhang L, et al. Dichotomy of genetic abnormalities in PEComas with therapeutic implications. Am J Surg Pathol. 2015;39(6):813–825. doi:10.1097/pas.0000000000000389
   PubMed Web of Science ®Google Scholar
• Armah HB, Parwani AV. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature. Diagn Pathol. 2007;2:45. doi:10.1186/1746-1596-2-45
   PubMed Web of Science ®Google Scholar
• Le P, Garg A, Brandao G, et al. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma. Curr Oncol. 2014;21(3):e518–20. doi:10.3747/co.21.1849
   PubMed Web of Science ®Google Scholar
• Okamoto S, Komura M, Terao Y, et al. Pneumothorax caused by cystic and nodular lung metastases from a malignant uterine perivascular epithelioid cell tumor (PEComa). Respirat Med Case Rep. 2017;22:77–82. doi:10.1016/j.rmcr.2017.06.011
   PubMedGoogle Scholar
• Tajima S, Koda K. Perivascular epithelioid cell tumor of the uterine cervix identified on a conventional cervical smear. Diagn Cytopathol. 2015;43(12):1011–1016. doi:10.1002/dc.23369
   PubMed Web of Science ®Google Scholar
• Stone JL, Batty T, Nicklin J. Cervical perivascular epithelioid cell tumour (PEComa) of the uterine cervix: cytological findings in a cervical smear. Cytopathology. 2013;24(4):272–273. doi:10.1111/j.1365-2303.2012.00989.x
   PubMed Web of Science ®Google Scholar
• Bonetti F, Pea M, Martignoni G, et al. PEC and sugar. Am J Surg Pathol. 1992;16(3):307–308. doi:10.1097/00000478-199203000-00013
   PubMed Web of Science ®Google Scholar
• Hornick JL, Fletcher CD. PEComa: what do we know so far? Histopathology. 2006;48(1):75–82. doi:10.1111/j.1365-2559.2005.02316.x
   PubMed Web of Science ®Google Scholar
• Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005;29(12):1558–1575. doi:10.1097/01.pas.0000173232.22117.37
   PubMed Web of Science ®Google Scholar
• Gulavita P, Fletcher CDM, Hirsch MS. PNL2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours. Histopathology. 2018;72(3):441–448. doi:10.1111/his.13369
   PubMed Web of Science ®Google Scholar
• Valencia-Guerrero A, Pinto A, Anderson WJ, et al. PNL2: a useful adjunct biomarker to HMB45 in the diagnosis of uterine perivascular epithelioid cell tumor (PEComa). Internat J Gynecolog Pathol. 2020;39(6):529–536. doi:10.1097/pgp.0000000000000653
   PubMed Web of Science ®Google Scholar
• Jeon IS, Lee SM. Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus. J Pediat Hematol. 2005;27(12):681–684. doi:10.1097/01.mph.0000193475.06870.d5
   PubMed Web of Science ®Google Scholar
• Yamamoto E, Ino K, Sakurai M, et al. Fertility-sparing operation for recurrence of uterine cervical perivascular epithelioid cell tumor. Rare Tumors. 2010;2(2):e26. doi:10.4081/rt.2010.e26
   PubMedGoogle Scholar
• Sanfilippo R, Jones RL, Blay JY, et al. Role of Chemotherapy, VEGFR Inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas). Clin Can Res. 2019;25(17):5295–5300. doi:10.1158/1078-0432.Ccr-19-0288
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835–840. doi:10.1200/jco.2009.25.2981
   PubMed Web of Science ®Google Scholar
• Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Anna Oncol. 2010;21(5):1135–1137. doi:10.1093/annonc/mdq044
   PubMed Web of Science ®Google Scholar
• Purwar R, Soni K, Shukla M, et al. TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review. World J Surg Oncol. 2022;20(1):62. doi:10.1186/s12957-021-02462-5
   PubMed Web of Science ®Google Scholar
• Xu J, Gong XL, Wu H, et al. Case report: gastrointestinal PEComa With TFE3 rearrangement treated with anti-VEGFR TKI apatinib. Front Oncol. 2020;10:582087. doi:10.3389/fonc.2020.582087
   PubMed Web of Science ®Google Scholar
• Liapi A, Mathevet P, Herrera FG, et al. VEGFR Inhibitors for uterine metastatic perivascular epithelioid tumors (PEComa) Resistant to mTOR Inhibitors. A case report and review of literature. Front Oncol. 2021;11:641376. doi:10.3389/fonc.2021.641376
   PubMed Web of Science ®Google Scholar
• Kwon BS, Suh DS, Lee NK, et al. Two cases of perivascular epithelioid cell tumor of the uterus: clinical, radiological and pathological diagnostic challenge. Eur J Med Res. 2017;22(1):7. doi:10.1186/s40001-017-0248-y
   PubMedGoogle Scholar
• Kopparthy P, Murphy M. Rapid and durable response with nab-sirolimus after everolimus failure in a patient with perivascular epithelioid cell tumors (PEComas) of the uterus. Cureus. 2021;13(5):e14951. doi:10.7759/cureus.14951
   PubMed Web of Science ®Google Scholar
• Gao F, Huang C, Zhang Y, et al. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Cancer Biol Ther. 2016;17(6):595–598. doi:10.1080/15384047.2016.1167290
   PubMed Web of Science ®Google Scholar
• Sui C, Wu J, Mei D, et al. Uterine perivascular epithelioid tumors (PEComas) with lung metastasis showed good responses to mTOR and VEGFR inhibitors: a case report. Front Oncol. 2022;12:797275. doi:10.3389/fonc.2022.797275
   PubMed Web of Science ®Google Scholar
• Fukunaga M. Perivascular epithelioid cell tumor of the uterus: report of four cases. Internat J Gynecolog Pathol. 2005;24(4):341–346. doi:10.1097/01.pgp.0000168515.83557.89
   PubMed Web of Science ®Google Scholar
• Ciarallo A, Makis W, Hickeson M, et al. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus: serial imaging with F-18 FDG PET/CT for surveillance of recurrence and evaluation of response to therapy. Clin. Nucl. Med. 2011;36(4):e16–9. doi:10.1097/RLU.0b013e31820ae032
   PubMed Web of Science ®Google Scholar
• Natella V, Merolla F, Giampaolino P, et al. A huge malignant perivascular epithelioid cell tumor (PEComa) of the uterine cervix and vagina. Pathol Res Pract. 2014;210(3):186–188. doi:10.1016/j.prp.2013.10.003
   PubMed Web of Science ®Google Scholar
• Ascione A, Martignoni G, d’Amati G, et al. Extremely late-onset pulmonary metastasis from uterine PEComa. Pathologica. 2022;114(4):312–315. doi:10.32074/1591-951x-762
   PubMed Web of Science ®Google Scholar
• Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638–648. doi:10.1259/0007-1285-26-312-638
   PubMed Web of Science ®Google Scholar
• Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tum Biol. 2010;31(4):363–372. doi:10.1007/s13277-010-0042-8
   PubMedGoogle Scholar
• Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394:287–91. doi:10.1038/28412
   PubMed Web of Science ®Google Scholar
• Northrup H, Krueger DA, Northrup H. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243–254. doi:10.1016/j.pediatrneurol.2013.08.001
   PubMed Web of Science ®Google Scholar
• McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186(12):1210–1212. doi:10.1164/rccm.201205-0848OE
   PubMed Web of Science ®Google Scholar
• Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104(11):971–979. doi:10.1093/qjmed/hcr116
   PubMed Web of Science ®Google Scholar
• McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021;9(11):1313–1327. doi:10.1016/s2213-2600(21)00228-9
   PubMed Web of Science ®Google Scholar
• Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Europ resp J. 2010;35(1):14–26. doi:10.1183/09031936.00076209
   PubMed Web of Science ®Google Scholar
• Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. Am J Respir Crit Care Med. 2017;196(10):1337–1348. doi:10.1164/rccm.201709-1965ST
   PubMed Web of Science ®Google Scholar
• Hayashi T, Kumasaka T, Mitani K, et al. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol. 2011;35(12):1776–1785. doi:10.1097/PAS.0b013e318235edbd
   PubMed Web of Science ®Google Scholar
• Clay MR, Gibson P, Lowell J, et al. Microscopic uterine lymphangioleiomyomatosis perivascular epithelioid cell neoplasm: a case report with the earliest manifestation of this enigmatic neoplasm. Internat J Gynecolog Pathol. 2011;30(1):71–75. doi:10.1097/PGP.0b013e3181efe08d
   PubMed Web of Science ®Google Scholar
• Prizant H, Sen A, Light A, et al. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. Molecul Endocrinol. 2013;27(9):1403–1414. doi:10.1210/me.2013-1059
   PubMedGoogle Scholar
• Ando H, Ogawa M, Watanabe Y, et al. Lymphangioleiomyoma of the uterus and pelvic lymph nodes: a report of 3 cases, including the potentially earliest manifestation of extrapulmonary lymphangioleiomyomatosis. Internat J Gynecolog Pathol. 2020;39(3):227–232. doi:10.1097/pgp.0000000000000589
   PubMed Web of Science ®Google Scholar
• Di Donato V, Giannini A, Bogani G. Recent advances in endometrial cancer management. J Clin Med. 2023;12(6):2241. doi:10.3390/jcm12062241
   PubMed Web of Science ®Google Scholar